The highly invasive and angiogenic characteristics of malignant gliomas depend on the production of growth factors and angiogenic factors. Heparin-binding growth-associated molecule (HB-GAM) is a secreted growth factor that is mitogenic for endothelial cells. To examine the expression profile of HB-GAM in malignant glioma cells, messenger ribonucleic acid (mRNA) expression was analyzed in 10 malignant glioma cell lines, two glioblastoma tissue specimens, and two normal brain tissue specimens by the reverse transcription-polymerase chain reaction. HB-GAM mRNA was expressed in all specimens including normal brain tissue specimens. Western blot analysis revealed that HB-GAM protein contents in glioma cell lines and glioblastoma tissues were 1.8 to 6.3 times higher than those in normal brain tissues. The effect of neutralizing anti-platelet-derived growth factor (PDGF) antibody was also examined on the production of HB-GAM in malignant glioma cells, since malignant glioma cells secrete PDGF that upregulates HB-GAM expression. Treatment of U251 and T98G glioblastoma cells with the anti-PDGF antibody did not affect the HB-GAM production. These results suggest that HB-GAM is overexpressed in malignant glioma cells and is involved in tumor growth.
Introduction
Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive, and are considered to be among the deadliest of human cancers. 20) Many growth factors as well as their receptors are expressed and function as important mediators in malignant glioma, so such factors are possible targets for therapeutic intervention. Recently, a new family of neurotrophic growth factors was identified, including the heparin-binding growth-associated molecule (HB-GAM) and midkine. 15) HB-GAM, also known as pleiotrophin, is an 18 kDa secreted protein belonging to this family of heparin-binding factors. 25, 31) HB-GAM shares 50% of its amino acid sequence homology with midkine, but no homology with other heparin-binding proteins. 18 ) HB-GAM is highly expressed in the developing rat nervous system and becomes downregulated in the adult. 25) Such widespread downregulation of HB-GAM is reversed in a number of cancers, and HB-GAM functions as a tumor growth factor and angiogenic factor. 15) However, the expression pattern of HB-GAM is not well characterized in malignant gliomas.
We previously showed that malignant glioma cells produce thrombospondin-1 (TSP-1), 11) which is involved in the motility of glioma cells. 1) TSP-1 can bind several cell surface molecules, including integrins 14, 35) and heparan sulfate proteoglycan (HSPG). 2) Recently, we found that malignant glioma cells express syndecans (manuscript submitted), which are major cell surface HSPGs. HB-GAM is one of the ligands that binds HSPG, 2) and may function as growth factor for malignant glioma cells.
In this study, we investigated the HB-GAM expression profile in 10 human malignant glioma cell lines, two glioblastoma tissue specimens, and two normal brain tissue specimens, and found that HB-GAM was overexpressed in malignant glioma cell lines and glioblastoma tissues compared to normal brain tissues. We also examined the effect of neutralizing anti-platelet-derived growth factor (PDGF) antibody on the production of HB-GAM in malig-
II. Ribonucleic acid (RNA) isolation
Human malignant glioma cells were cultured in 9 cm dishes. Subconfluent tumor cells were collected after incubation with 0.25% trypsin and 0.02% ethylenediaminetetra-acetic acid (EDTA), and then washed once with phosphate-buffered saline (PBS). Total RNA was isolated by the single-step method 32) using ISOGEN (Nippon Gene, Toyama) according to the manufacturer's instructions. Total RNA was also isolated from the two glioblastoma specimens and two normal brain specimens obtained at surgery.
III. Reverse transcription-polymerase chain reaction (RT-PCR) analysis
RT-PCR was performed using 0.5 mg total RNA, 0.2 mM primers, and a kit for RT-PCR (Takara Shuzo, Shiga). Primer sequences 41) were as follows: sense, 5'-GGTAAGCTTAGAGGACGTTTCCAACTCAA-3'; antisense, 5'-GGTCTCGAGTATGTTCCACAGGTG-ACATC-3'.
PCR amplification was performed for 30 cycles in a deoxyribonucleic acid (DNA) thermocycler (Takara Shuzo) using denaturation for 30 seconds at 949 C, annealing for 30 seconds at 569 C, and extension for 1 minute at 729 C. Amplified PCR products were analyzed on 1.5% agarose gels. For direct sequencing, the PCR products were purified from agarose gels using the QIAquick gel extraction kit (Qiagen, Tokyo) according to the manufacturer's instructions.
IV. DNA sequence analysis
To confirm the identity of the PCR products, the putative HB-GAM complementary DNA (cDNA) fragments were amplified by RT-PCR. The cDNA was cloned into a pCR II-TOPO vector (Invitrogen, Carlsbad, Calif., U.S.A.) and then introduced into Escherichia coli cells. White and blue screening was performed to select the plasmid carrying HB-GAM. After purification of the plasmid, the digestion with EcoRI was carried out and then the DNA fragment containing HB-GAM was extracted from the gel using the QIAquick gel extraction kit. The nucleotide sequence of the DNA fragment was determined by the dideoxy termination method.
V. Western blot analysis
The human malignant glioma cells were cultured in 9 cm dishes. Subconfluent tumor cells were collected after incubation with 0.25% trypsin and 0.02% EDTA, and washed once with PBS. The cell pellets were lysed with RIPA buffer (5 M NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 M Tris-HCl, pH 8.0). The glioblastoma tissues and normal brain tissues were homogenized and lysed in the same buffer. The lysates were passed through a 21 gauge syringe needle four to six times, then kept on ice for 30 minutes and centrifuged at 12009rpm for 15 minutes at 49 C. The lysates (40 mg protein) were separated on a 16% sodium dodecyl sulfate polyacrylamide gel (TEFCO, Tokyo) and electroblotted on polyvinylidene difluoride membrane (Millipore, Bedford, Mass., U.S.A.). The membrane was treated with 10% skim milk. After washing, the membrane was incubated with goat anti-human HB-GAM polyclonal antibody (1:400) (Santa Cruz Biotechnology, Santa Cruz, Calif., U.S.A.) for 1 hour at room temperature. After washing, the membrane was treated with anti-goat antibody conjugated with alkaline phosphatase (EY Laboratories, San Mateo, Calif., U.S.A.) for 30 minutes at room temperature. After washing, the membrane was equilibrated with detection buffer for 3 minutes and then incubated with CDP-Star (Roche Diagnostics, Mannheim, Germany) substrate to develop the signal. The immunoblot signals were visualized by chemiluminescence and recorded using a Fuji LAS1000 Lumino Image Analyzer (Fuji Photo Film, Tokyo). As an internal HB-GAM Expression in Glioma control for protein content, the lysates were analyzed using anti-actin antibody (Santa Cruz Biotechnology). The HB-GAM content in the lysates was evaluated by densitometry using a National Institutes of Health image analysis system. To examine the correlation between the level of HB-GAM protein and the density of immunoblot signal, the lysate of T98G cells was selected since it showed a high value of HB-GAM protein. The lysates (5, 10, 20, 30, 40, and 50 mg protein) were loaded on a gel and analyzed as described above.
VI. Effect of neutralizing anti-PDGF antibody on HB-GAM production U251 and T98G cells were cultured in 6-well plates and subconfluent cells were treated with 20 mg/ml of neutralizing anti-PDGF-BB antibody (TECHNE, Minneapolis, Minn., U.S.A.) for 24 hours. U251 cells were also treated with the antibody for 48 hours. The anti-PDGF-BB antibody also neutralizes the activity of PDGF-AB and PDGF-AA partially. Normal goat immunoglobulin was used as negative control. After the treatment the tumor cells were collected using 0.25% trypsin and 0.02% EDTA. The cell lysates were obtained and the production of HB-GAM was analyzed by Western blotting as described above.
Results

I. Expression of HB-GAM messenger RNA
(mRNA) in malignant glioma cell lines and normal brain tissues Figure 1 shows the mRNA expression of HB-GAM as measured by RT-PCR analysis in the 10 human malignant glioma cell lines, two glioblastoma tissue specimens, and two normal brain tissue specimens. A prominent PCR product of 530 bp could be detected in all lines. There was no clear difference in the amounts of amplified product between the tumor samples and normal brain tissues. DNA sequence analysis confirmed that the sequence of the PCR product was completely identical to the reported sequence for HB-GAM.
II. Expression of HB-GAM protein in malignant
glioma cell lines Figure 2 shows the expression patterns of HB-GAM protein in the 10 tumor cell lines, two glioblastoma tissue specimens, and two normal brain tissue specimens by Western blot analysis. The density of each band was evaluated using densitometry and the relative density was determined by normalization of the values using that of DFB melanoma cell lysate which was loaded in each gel as a positive control (Fig. 3) . The relative density of DFB cells was determined as 1.0, and those of other samples were expressed as relative values compared to that of DFB cells. The dose of the lysate protein of T98G cells showed nearly linear correlation with the density of each immunoblot signal. Therefore, it was possible to compare the contents of HB-GAM protein in the glioma cell lines and glioblastoma tissues with those of normal brain tissues. The contents of HB-GAM protein in 10 glioma cell lines and two glioblastoma tissues were 1.8 to 6.3 times higher than those in normal brain tissues. The relative densities of the three glioblastoma cell lines (T98G, U251, and YMG1) were 1.3, 1.0, and 1.6, respectively. The relative densities of the two glioblastoma tissues and two normal brain tissue specimens were 0.49 and 0.78, and 0.24 and 0.25, respectively.
III. Effect of neutralizing anti-PDGF antibody on HB-GAM production
The treatment of U251 and T98G cells with neutralizing anti-PDGF-BB antibody did not alter the production of HB-GAM (Fig. 4) .
Discussion I. Expression of HB-GAM in malignant glioma cells
The present study showed that malignant glioma cell lines and glioblastoma tissues overexpressed HB-GAM compared to normal brain tissues. Recently, expression of HB-GAM has been determined in malignant glioma cells mainly by RT-PCR and, in some cases, immunohistochemistry and Western blotting. 24) Our results are consistent with these previous findings. However, the expression profile of HB-GAM protein is less well known and cultivated adult human astrocytes did not express HB-GAM by RT-PCR analysis. 24) In contrast, we showed that the variable levels of HB-GAM protein in 10 malignant glioma cell lines and two glioblastoma tissues measured by Western blot analysis were 1.8 to 6.3 times higher than those in normal brain tissues. HB-GAM mRNA is strongly expressed during the early postnatal growth phase of rat brain as compared with embryonic or adult brain, suggesting developmental regulation of the gene expression. 25) These previous findings are consistent with the present HB-GAM Expression in Glioma results and suggest that HB-GAM is constitutively expressed at a low level in the adult human brain as observed in mice, rats, and bovines, 3, 12, 13, 15, 25) and is overexpressed in malignant gliomas.
HB-GAM is produced in some other types of tumors, including neuroblastomas, 27) meningiomas, 21) melanomas, 5) breast cancers, 7) and pancreatic and colon cancers. 40) The present study used the DFB melanoma cell line as a positive control for HB-GAM production. The expression levels of HB-GAM protein in malignant glioma cells were mostly comparable to that of DFB melanoma cells. The mechanism of HB-GAM overexpression is unclear at present. The human HB-GAM gene is localized on chromosome 7, band q33-34, 17) and a part of this chromosome is often amplified in gliomas. 34) There is a serum response element in the promoter region of HB-GAM gene, 17) which may account for the finding that HB-GAM is upregulated by a PDGF. 16) However, the present study using a neutralizing antibody showed that PDGF did not affect the production of HB-GAM in malignant glioma cells. This result suggests that the HB-GAM overexpression in malignant glioma cells is not regulated by PDGF receptor signaling pathway. The exact mechanism of the HB-GAM overexpression remains to be clarified.
II. HB-GAM as a growth factor and its receptors
HB-GAM functions as a growth factor for several tumors. HB-GAM expression is correlated with the L. Zhang et al.
highly metastatic behavior of breast cancer. 8) In human melanoma cells that express high levels of pleiotrophin mRNA, pleiotrophin-targeted ribozymes quench production of pleiotrophin, inhibit colony formation of the cells, and prevent tumor growth in mice. 4) Furthermore, targeting of HB-GAM mRNA with ribozymes prevents growth of choriocarcinomas 33) and pancreatic cancer cells. 39) There are four receptors for HB-GAM: receptortype protein tyrosine phosphatase z/b, 19) anaplastic lymphoma kinase (ALK), 38) syndecan-1, 26) and syndecan-3. 30) The first two receptors for HB-GAM are expressed in glioma cell lines. 6, 28, 29) HB-GAM binds to and functionally inactivates the catalytic activity of receptor-type protein tyrosine phosphatase, resulting in increased levels of tyrosine phosphorylation of b-catenin to initiate downstream signaling. 23) Glioblastoma cells overexpress ALK and the HB-GAM-ALK pathway is essential for growth of glioblastoma cells. 29) HB-GAM activates both the Ras/mitogen-activated protein kinase and phosphatidylinositol-3 kinase/Akt signaling axes, 36) and both pathways are implicated in glial tumorigenesis. 10) We previously found the expression of all types of syndecans (syndecan-1 to -4) in malignant glioma cells (manuscript submitted). Syndecans function as co-receptors for a variety of ligands and help the binding of ligands to the specific receptors, resulting in activation of signal transduction. 2) HB-GAM signal transduction appears to involve both HSPG and transmembrane-acting kinases. 15) This is similar to the mechanism demonstrated for fibroblast growth factor receptor. 22, 37) These results suggest that HB-GAM functions as a tumor growth factor.
III. Conclusion
Malignant glioma cells overexpress HB-GAM compared to normal brain tissues. However, a mechanism of HB-GAM overexpression is still unknown. The present results suggest that the HB-GAM expression in malignant glioma cells is involved in tumor growth. 
